Could treatment with botulinum toxin protect against subsequent infection with COVID-19? - 24/06/21

Doi : 10.1016/j.jormas.2021.06.003

D. Batifol ^a,^⁎ , P.J. Finiels ^b, S. Galmiche ^a, P. Jammet ^a, M. de Boutray ^a
^a Maxillofacial Surgery Department, Montpellier University Hospital Gui de Chauliac, Montpellier, France
^b Department of Orthopedics, Traumatology and Spine Neurosurgery, Alès General Hospital, Alès, France

^⁎Corresponding author at: Maxillofacial Surgery Department, Gui de Chauliac Hospital, 80 avenue Augustin Fliche, Montpellier cedex 5 34295, France.Maxillofacial Surgery DepartmentGui de Chauliac Hospital80 avenue Augustin FlicheMontpellier cedex 534295France

conectar o crear una cuenta

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Thursday 24 June 2021
This article has been published in an issue click here to access

Abstract

We report comparative results, over three months, of the impact of SARS-CoV2 in our patients injected with botulinum toxin for functional purposes, compared to the general population. Botulinum neurotoxin type A (BoNT/A) is known to block acetylcholine (ACh) as well as many other neuroreceptors and neuromodulators. The recent mention of a potential protective effect of nicotine in COVID 19, by blocking ACh, attracted our attention and guided the present study.

Our results show a significant difference between the number of infected individuals in the general population and the number of patients injected with BoNT/A who showed signs of COVID 19.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Botulinum toxin, Acetylcholine blocking